Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

PH-762 Demonstrates Safety and Local Efficacy in Skin Cancer

Phio Pharmaceuticals reveals promising results for PH-762, a novel siRNA therapy targeting skin cancer, showcasing effective tumor clearance and safety.

Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Company Background and Business Model Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company specializing in RNA interference (RNAi) therapies for cancer. The company was co-founded by Nobel laureate Dr. Craig Mello, a discoverer of RNAi, leveraging that legacy to develop its proprietary INTASYL™ gene-silencing technology phiopharma.com. Originally known as RXi Pharmaceuticals (founded ~2011), Phio rebranded and refocused on im…

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Pathologic Clearance: 100% Tumor Clearance (Complete Response) in One Patient, Greater than 90% (Near Complete Response) in Second Patient,

Smarter AI can detect skin cancer much better

A team of researchers from Fox Chase Cancer Center and Temple University has developed a new way to improve how artificial intelligence (AI) detects skin cancer, especially in people with darker skin tones. This work could lead to earlier and more accurate diagnoses for everyone, no matter their skin color. The research, published in the […] The post Smarter AI can detect skin cancer much better appeared first on Knowridge Science Report.